• Vaccine Name: Ebola virus recombinant adenovirus vector vaccine ADV−GP/NP
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004072
• Type: Recombinant vector vaccine
• Status: Research
• GP from Zaire ebolavirus gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector adenoviral (ADV) expressed Ebola glycoprotein (GP) (Sullivan et al., 2003b).
  • Detailed Gene Information: Click Here.
• NP from Zaire Ebola virus gene engineering:
  • Type: Recombinant vector construction
  • Description: Vector adenoviral (ADV) expressed Ebola nucleoprotein (NP) (Sullivan et al., 2003b).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0000136
• Preparation: To make ADV-GP, the BamHI/EcoRI fragment of GP(Z) was digested from PGEM-3Zf(-)-GP, treated with Klenow, and inserted into HindIII/XbaI/Kle/CIP-treated pRc/CMV plasmid. The resulting plasmid was digested by NruI/DraIII and treated with Klenow. The NruI/DraIII/Kle fragment containing the CMV enhancer, GP(Z) DNA and bovine growth hormone polyadenylation signal was inserted into the BgIII site of the adenoviral shuttle plasmid pAdBgIII26. The adenovirus, a first generation dl 309-based Ad5 vector, contained a deletion in E1 to render the vector replication defective and a partial deletion/substitution in E3, which disrupts the coding sequences for the E3 proteins with a relative molecular mass of 14,700, 14,500 and 10,400, respectively (Sullivan et al., 2000).
• Virulence:
• Description: ADV−GP consists of an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) (Sullivan et al., 2003).

Monkey Response

• Host Strain: Cynomolgus macaque
• Vaccination Protocol: Cynomolgus macaques were immunized with ADV−GP and ADV−NP, followed by boosting 9 weeks later (Sullivan et al., 2003).
• Persistence: None noted
• Side Effects: None noted
• Challenge Protocol: One week after the boost, animals were challenged with either a low or high dose of a 1995 isolate of Ebola virus Zaire.
• Efficacy: In the saline-injected control animals these doses were uniformly fatal 6−12 days afterwards. In contrast, the ADV−GP/NP immunized monkeys were completely protected. Analysis of the cell-mediated and humoral immune responses revealed significant increases in the CD8+ T-cell response to Ebola antigens by intracellular cytokine staining for interferon (IFN)-, seen before exposure to virus, in contrast to control animals where no response was seen. Similarly, antibody titres to the virus were stimulated in vaccinated animals, which minimally increased after the viral challenge (Sullivan et al., 2003).